We have brought together world-class investors from both the biotech and tech fields, including venture capital firms Polaris Partners, who initially seeded CAMP4, and Andreessen Horowitz, who led our Series A round.

Our investors share our commitment to deliver on the promise of our technology, our mission to revolutionzie how medicines are discovered and developed, and our vision to create a world where a treatment for every disease is possible.

Partnering to Capitalize on the Potential

Our platform enables expansive opportunities across multiple therapeutic areas and modalities. Given the enormity of the potential, we can’t do it all alone. We intend for our approach and unparalleled understanding of transcriptional machinery and gene expression to revolutionize how our industry approaches drug discovery and development.

Partnering with biopharma companies with expertise in a given therapeutic area or modality is integral to maximizing the potential of our platform for patients. Our aim is to empower partners with a rapid, efficient approach to targeting the diseases that matter most to them.